Tacrolimus Decreases Albuminuria in Patients with IgA Nephropathy and Normal Blood Pressure: a Double-blind Randomized Controlled Trial of Efficacy of Tacrolimus on IgA Nephropathy

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Aug 27

PMID 23977072

Citations 19

Authors

Yong-Chul Kim

Ho Jun Chin

Ho Suk Koo

Suhnggwon Kim

Affiliations

Soon will be listed here.

Abstract

Background: Treatment remains uncertain for IgA nephropathy patients with mild to moderate proteinuria, for whom anti-hypertensive medication or the RAS blocker is not applicable due to low blood pressure.

Trial Design: A double blinded randomized trial.

Methods: The anti-proteinuric effect of tacrolimus was explored for 40 biopsy-proven mild IgA nephropathies for 16 weeks. We randomly assigned patients either to receive tacrolimus or placebo with stratification by using a renin angiotensin system blocker. The primary outcome was the percentage change of final UACR compared to the baseline value (pcUACR).

Results: The mean value of pcUACR at 12-week and 16-week visits (primary outcome) was decreased more in the Tac group compared to the control group (-52.0±26.4 vs -17.3±29.3%, p = 0.001). At each visit, pcUACR was also decreased more in the Tac group compared to the control group. In the Tac group, the pcUACRs were -60.2±28.2%, -62.2±33.9%, -48.5±29.8%, and -55.5±24.0%, and, in the control group, -6.8±32.2%, -2.5±35.9%, -12.7±34.2%, and -21.9±30.6%, at 4-week, 8-week, 12-week, and 16-week visits, respectively. The pre-defined secondary outcomes were better in the Tac group compared to the control group. The frequency of decrease in pcUACR and percentage change of UPCR (pcUPCR) ≥50% at 16 weeks were 65.0% (13/20) and 55.0% (11/20)in the Tac group, and 25.0% (5/20) and 15.0% (3/20), in the control group, respectively (p = 0.025 for pcUACR and p = 0.019 for pcUPCR). However, tacrolimus wasn't effective with a dose of 0.05 mg/kg/day in patients taking ARB. The adverse events were tolerable.

Conclusion: Tacrolimus effectively reduced proteinuria in IgA nephropathy with normal blood pressure. This suggested that tacrolimus could be an alternative to corticosteroid and RAS blocker for IgA nephropathy patients who cannot endure anti-hypertensive medication.

Trial Registration: Clinicaltrial.gov NCT1224028.

Citing Articles

Navigating Adult-Onset IgA Vasculitis-Associated Nephritis.

Gan M, Chua F, Chang Z, Chua Y, Chan G Life (Basel). 2024; 14(8).

PMID: 39202674 PMC: 11355272. DOI: 10.3390/life14080930.

Potential benefits and related treatment effects of calcineurin inhibitors combined with steroid for IgA nephropathy: a systematic review and meta-analysis.

Li Z, Yang Z, Ji M Int Urol Nephrol. 2023; 55(9):2227-2236.

PMID: 36856924 DOI: 10.1007/s11255-023-03524-1.

Efficacy and Safety of Immunosuppressive Monotherapy Agents for IgA Nephropathy: A Network Meta-Analysis.

Han S, Yao T, Lu Y, Chen M, Xu Y, Wang Y Front Pharmacol. 2021; 11:539545.

PMID: 33551793 PMC: 7862876. DOI: 10.3389/fphar.2020.539545.

The efficacy and safety of immunosuppressive therapies in the treatment of IgA nephropathy: A network meta-analysis.

Tan J, Dong L, Ye D, Tang Y, Hu T, Zhong Z Sci Rep. 2020; 10(1):6062.

PMID: 32269271 PMC: 7142138. DOI: 10.1038/s41598-020-63170-w.

Immunosuppressive agents for treating IgA nephropathy.

Natale P, Palmer S, Ruospo M, Saglimbene V, Craig J, Vecchio M Cochrane Database Syst Rev. 2020; 3:CD003965.

PMID: 32162319 PMC: 7066485. DOI: 10.1002/14651858.CD003965.pub3.

References

Radford Jr M, Donadio Jr J, Bergstralh E, Grande J . Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol. 1997; 8(2):199-207. DOI: 10.1681/ASN.V82199. View

Koyama A, Igarashi M, Kobayashi M . Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases. Am J Kidney Dis. 1997; 29(4):526-32. DOI: 10.1016/s0272-6386(97)90333-4. View

Berthoux F, Mohey H, Laurent B, Mariat C, Afiani A, Thibaudin L . Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol. 2011; 22(4):752-61. PMC: 3065230. DOI: 10.1681/ASN.2010040355. View

Li X, Li H, Chen J, He Q, Lv R, Lin W . Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome. Nephrol Dial Transplant. 2007; 23(6):1919-25. DOI: 10.1093/ndt/gfm637. View

Boots J, van Duijnhoven E, Christiaans M, Nieman F, van Suylen R, van Hooff J . Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients. Transpl Int. 2002; 14(6):370-83. DOI: 10.1007/s001470100002. View

Chen W, Liu Q, Liao Y, Yang Z, Chen J, Fu J . Outcomes of tacrolimus therapy in adults with refractory membranous nephrotic syndrome: a prospective, multicenter clinical trial. Am J Med Sci. 2012; 345(2):81-7. DOI: 10.1097/MAJ.0b013e31824ce676. View

Zhou Y, Tang L, Guo S, Jin Z, Wu M, Zang J . Steroids in the treatment of IgA nephropathy to the improvement of renal survival: a systematic review and meta-analysis. PLoS One. 2011; 6(4):e18788. PMC: 3075273. DOI: 10.1371/journal.pone.0018788. View

Gutierrez E, Zamora I, Ballarin J, Arce Y, Jimenez S, Quereda C . Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J Am Soc Nephrol. 2012; 23(10):1753-60. PMC: 3458461. DOI: 10.1681/ASN.2012010063. View

DAmico G . The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987; 64(245):709-27. View

10.

Li P, Ho K, Szeto C, Yu L, Lai F . Prognostic indicators of IgA nephropathy in the Chinese--clinical and pathological perspectives. Nephrol Dial Transplant. 2002; 17(1):64-9. DOI: 10.1093/ndt/17.1.64. View

11.

Ferraro P, Ferraccioli G, Gambaro G, Fulignati P, Costanzi S . Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial. Nephrol Dial Transplant. 2008; 24(1):156-60. DOI: 10.1093/ndt/gfn454. View

12.

Arikan H, Koc M, Cakalagaoglu F, Eren Z, Segal M, Tuglular S . Tacrolimus rescue therapy in resistant or relapsing cases of primary glomerulonephritis. J Nephrol. 2008; 21(5):713-21. View

13.

Geddes C, Rauta V, Gronhagen-Riska C, Bartosik L, Jardine A, Ibels L . A tricontinental view of IgA nephropathy. Nephrol Dial Transplant. 2003; 18(8):1541-8. DOI: 10.1093/ndt/gfg207. View

14.

Uchino A, Tsukamoto H, Nakashima H, Yoshizawa S, Furugo I, Mitoma H . Tacrolimus is effective for lupus nephritis patients with persistent proteinuria. Clin Exp Rheumatol. 2010; 28(1):6-12. View

15.

Chang J, Kim D, Kim H, Park S, Yoo T, Kim B . Changing prevalence of glomerular diseases in Korean adults: a review of 20 years of experience. Nephrol Dial Transplant. 2009; 24(8):2406-10. DOI: 10.1093/ndt/gfp091. View

16.

Neelakantappa K, Gallo G, Baldwin D . Proteinuria in IgA nephropathy. Kidney Int. 1988; 33(3):716-21. DOI: 10.1038/ki.1988.57. View

17.

Lee T, Oh K, Joo K, Kim Y, Ahn C, Han J . Tacrolimus is an alternative therapeutic option for the treatment of refractory lupus nephritis. Lupus. 2010; 19(8):974-80. DOI: 10.1177/0961203310366573. View

18.

Nakamura T, Inoue T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y . Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy. Am J Hypertens. 2007; 20(11):1195-201. DOI: 10.1016/j.amjhyper.2007.06.003. View

19.

Fan L, Liu Q, Liao Y, Li Z, Ji Y, Yang Z . Tacrolimus is an alternative therapy option for the treatment of adult steroid-resistant nephrotic syndrome: a prospective, multicenter clinical trial. Int Urol Nephrol. 2012; 45(2):459-68. DOI: 10.1007/s11255-012-0205-1. View

20.

Horita Y, Tadokoro M, Taura K, Ashida R, Hiu M, Taguchi T . Prednisolone co-administered with losartan confers renoprotection in patients with IgA nephropathy. Ren Fail. 2007; 29(4):441-6. PMC: 2409178. DOI: 10.1080/08860220701260511. View